Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zodasiran - Arrowhead Pharmaceuticals

Next Previous
Drug Profile

Zodasiran - Arrowhead Pharmaceuticals

Alternative Names: ARO-ANG3; ARO-ANG33; VSA-003

Latest Information Update: 01 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Arrowhead Pharmaceuticals
  • Class Antihyperlipidaemics; Cardiovascular therapies; Small interfering RNA
  • Mechanism of Action ANGPTL3 protein expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Dyslipidaemias
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hyperlipoproteinaemia type II
  • Phase II Dyslipidaemias

Most Recent Events

  • 25 Jun 2025 Arrowhead Pharmaceuticals plans a phase III trial for Hypercholesterolaemia (In adolescents, In adults, In elderly) in June 2025 (SC) (NCT07037771)
  • 17 Jun 2025 Phase-III clinical trials in Hyperlipoproteinaemia type II (In adolescents, In the elderly, In adults) in USA (SC) (NCT07037771)
  • 02 Dec 2024 Visirna Therapeutics plans a phase III trial for Hypercholesterolemia (In adolescents, In adults, In the elderly) in China (SC, Injection) (NCT06712771)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top